TSE:CTX Crescita Therapeutics (CTX) Stock Price, News & Analysis C$0.56 0.00 (0.00%) As of 05/9/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About Crescita Therapeutics Stock (TSE:CTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Crescita Therapeutics alerts:Sign Up Key Stats Today's RangeC$0.56▼C$0.5650-Day RangeC$0.51▼C$0.6052-Week RangeC$0.41▼C$0.69VolumeN/AAverage Volume14,579 shsMarket CapitalizationC$10.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCrescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.Read More… Receive CTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescita Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CTX Stock News HeadlinesCrescita Therapeutics Inc. (CRRTF)November 24, 2024 | finance.yahoo.comChordia Therapeutics Advances Cancer Drug DevelopmentNovember 20, 2024 | markets.businessinsider.comThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for it: "Elon Time." But this time... it’s different. A fleet of autonomous robotaxis is scheduled to be unleashed on the streets of Austin, Texas, this June.May 12, 2025 | Brownstone Research (Ad)Promising Phase 1 Results of Compass Therapeutics’ CTX-471 Highlight Potential for Advanced Solid Tumors TreatmentNovember 11, 2024 | markets.businessinsider.comCompass Therapeutics presents biomarker data related to CTX-471November 8, 2024 | markets.businessinsider.comCrescita Therapeutics Announces Approval of Normal Course Issuer BidSeptember 24, 2024 | businesswire.comCrescita Therapeutics Inc. Reports Second Quarter 2024 ResultsAugust 7, 2024 | finanznachrichten.deCrescita Reports Second Quarter 2024 ResultsAugust 7, 2024 | financialpost.comSee More Headlines CTX Stock Analysis - Frequently Asked Questions How have CTX shares performed this year? Crescita Therapeutics' stock was trading at C$0.58 at the start of the year. Since then, CTX stock has decreased by 3.4% and is now trading at C$0.56. View the best growth stocks for 2025 here. How do I buy shares of Crescita Therapeutics? Shares of CTX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Crescita Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crescita Therapeutics investors own include Baytex Energy (BTE), Argonaut Gold (AR), Birchcliff Energy (BIR), CBTX (CBTX), Crescent Point Energy (CPG), Enbridge (ENB) and IMV (IMV). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CTX CIKN/A Webwww.crescitatherapeutics.com Phone+1-905-6734295FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-2,614,925.18 Net Margins-15.73% Pretax MarginN/A Return on Equity-15.60% Return on Assets-8.26% Debt Debt-to-Equity Ratio5.77 Current Ratio2.70 Quick Ratio2.29 Sales & Book Value Annual SalesC$16.62 million Price / Sales0.62 Cash FlowC$0.47 per share Price / Cash Flow1.20 Book ValueC$0.83 per share Price / Book0.67Miscellaneous Outstanding Shares18,406,184Free FloatN/AMarket CapC$10.31 million OptionableNot Optionable Beta1.69 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (TSE:CTX) was last updated on 5/12/2025 by MarketBeat.com Staff From Our PartnersThis next market event could mean total financial ruin for someYou think the volatility is over? Think again … Because it’s just getting started. In fact, according...Weiss Ratings | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescita Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescita Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.